The long-term efficacy and tolerability of donepezil in patients with vascular dementia
|
|
- Tracey Gaines
- 6 years ago
- Views:
Transcription
1 RESEARCH ARTICLE The long-term efficacy and tolerability of donepezil in patients with vascular dementia David Wilkinson 1, Gustavo Róman 2, Stephen Salloway 3, Jane Hecker 4, Karyn Boundy 5, Dinesh Kumar 6, Holly Posner 7 and Rachel Schindler 7 1 Memory Assessment and Research Centre, Moorgreen Hospital, Southampton, UK 2 University of Texas Medical School at San Antonio, San Antonio, TX, USA 3 Memory and Aging Program, Butler Hospital, Providence, RI, USA 4 Memory Disorders Study Unit, Repatriation General Hospital, Daw Park, Australia 5 Department of Neurology, Queen Elizabeth Hospital, Woodville, Australia 6 Eisai Inc., Woodcliff Lake, NJ, USA 7 Pfizer Inc., New York, NY, USA Correspondence to: D. Wilkinson, David.Wilkinson@hantspt-sw.nhs.uk Objective: To determine the long-term tolerability and efficacy of donepezil in patients with vascular dementia (VaD). Methods: International, multicentre, open-label, 30-week extension study of two 24-week, randomised, double-blind, placebo-controlled studies. Participants were ambulatory adults (59% female; mean age, ) with a diagnosis of possible or probable VaD and without a diagnosis of Alzheimer s disease, who were medically stable and had completed one of two double-blind studies. All patients received donepezil 5 mg/day for the first 6 weeks, then 10 mg/day (clinician approval required). Assessments were performed at week 6 and every 12 weeks thereafter. The main outcome measure was the Alzheimer s disease Assessment Scale-cognitive subscale (ADAS-cog). Safety/tolerability measures included adverse events (AEs) and physical and laboratory evaluations. Results: Of 1219 eligible patients, 885 (72.6%) were enrolled, of which 707 (79.9%) completed the study; 127 (14.4%) patients discontinued due to AEs. A mean reduction ( points) from double-blind study baseline score to week 54 (end of open-label study) on the ADAS-cog was observed for patients who received donepezil continuously for 54 weeks. ADAS-cog scores remained stable in the group that initiated donepezil treatment during the extension study. Most common donepezil-related AEs were nausea (occurring in 5.3%) and diarrhoea (8.8%); no unexpected AEs attributable to donepezil occurred. Conclusion: These data suggest that donepezil improves cognition for up to 54 weeks in patients with VaD. Patients initiating donepezil in this extension study did not perform as well on the primary outcome measure as those initiating donepezil in the double-blind study. Copyright # 2009 John Wiley & Sons, Ltd. Key words: vascular dementia; donepezil; cholinesterase inhibitor; long-term trial; safety; tolerability; efficacy History: Received 20 January 2009; Accepted 21 May 2009; Published online 21 July 2009 in Wiley InterScience ( DOI: /gps.2340 Introduction Vascular dementia (VaD), one of the most common forms of dementia (Dubois and Hebert, 2001), results from ischaemic injury to brain regions serving memory, cognition and behaviour. In many countries throughout the world, there is currently no approved therapy for the symptomatic treatment of VaD (Doody et al., 2001b), and treatment strategies generally focus on the control of underlying cardiovascular risk factors such as the treatment of hypertension, correction of arrhythmias, smoking cessation, management of
2 306 D. Wilkinson et al. hyperlipidaemia and control of metabolic disorders such as diabetes. Given that brain lesions in patients with VaD may produce cholinergic dysfunction similar to that seen in patients with Alzheimer s disease (AD) (Tohgi et al., 1996), donepezil, a cholinesterase inhibitor (ChEI) approved for the treatment of AD, was investigated for the treatment of VaD. There have been two published 24-week, double-blind, placebo-controlled trials of donepezil in patients with possible or probable VaD (Black et al., 2003; Wilkinson et al., 2003), diagnosed clinically and radiologically using NINDS-AIREN criteria (Roman et al., 2005). A combined analysis of these studies (N ¼ 1219) showed that donepezil provided significant improvements at study end compared with placebo for cognition at both 5 and 10 mg/day doses, and for global function at the 5 mg/ day dose; donepezil was also well tolerated (Roman et al., 2005). A third, currently unpublished, trial of donepezil for VaD has been conducted, which was very similar in scope and structure to the two published trials, except that screening computed tomography or magnetic resonance imaging scans were reviewed centrally (Roman et al., 2006). As a result of available trial data, donepezil is now licensed for the treatment of VaD in Romania, India, South Korea, Thailand, Vietnam, New Zealand and the Philippines. The objective of the current study, an open-label extension of the original double-blind studies (Black et al., 2003; Wilkinson et al., 2003), was to determine the long-term safety and sustainability of efficacy in donepezil-treated patients, and to compare the effect of a delayed start to therapy in the placebo patients with effects in patients continually treated with donepezil. Methods Study design This was an open-label, 30-week extension study of two 24-week, randomised, double-blind, placebo-controlled, parallel-group studies in patients with possible or probable VaD. The study designs and results for the original trials have been published previously (Black et al., 2003; Wilkinson et al., 2003). Study sites conducted at 100 sites in the US, UK and Europe. For a subset of sites in the United Kingdom, Ireland, Germany and Australia, the study was extended for an additional 36 weeks (total extension of 66 weeks); this was for investigators who specifically made the request for their patient(s). Due to a small number of evaluable patients entering the additional 36-week extension phase ( 77 patients per original treatment group), as well as the potential for selection bias, efficacy data beyond the original 30-week extension were not statistically viable and are not presented in the current report. Safety findings from the additional 36- week extension are reported. Study entry criteria All patients who completed the double-blind studies were eligible for entry into the open-label study. Entry criteria for the double-blind studies have been described previously (Black et al., 2003; Wilkinson et al., 2003; Roman et al., 2005). Briefly, men and women aged at least 40 years with a diagnosis of probable or possible VaD of at least 3 months duration, Mini- Mental State Examination (MMSE) scores between 10 and 26, and with clinical and radiological evidence of cerebrovascular disease were included. Patients with hypertension, diabetes, cardiac disease or stroke were included provided these conditions had been stable for at least 3 months. Patients with AD or other neurodegenerative disorders were excluded, as were those with major psychiatric disorders or a history of drug or alcohol abuse. Most concomitant medications were permitted during the study, with the exception of other ChEIs and anticholinergics. All patients (or their legal representative) and their caregivers provided voluntary, written informed consent for participation in the study. This study was conducted in accordance with the ethical principles of the Declaration of Helsinki, as amended, and in accordance with local laws and regulations, whichever afforded the greater protection for the participant. Protocol In this open-label extension, all patients received donepezil 5 mg/day for the first 6 weeks and 10 mg/day thereafter, if approved by a clinician (irrespective of their assigned group during the double-blind studies), for a total of 30 weeks. Patients were assessed at week 6 and thereafter at 12-week intervals. In the subset of patients participating in the additional study extension, donepezil was continued at the same dosage and assessments were performed at weeks 42, 54 and 66. Vital signs and adverse events (AEs) were monitored at each assessment. A physical and neurological examination was also conducted and laboratory tests (clinical chemistry, haematology and urinalysis) performed.
3 Long-term use of donepezil for vascular dementia 307 Outcome measures The primary efficacy measure was the Alzheimer s disease Assessment Scale- cognitive subscale (ADAScog), a measure of cognitive function. Secondary efficacy outcome measures were the Clinical Dementia Rating-Sum of the Boxes (CDR-SB), a measure of overall disease severity; the MMSE, a second measure of cognitive function; and the Alzheimer s Disease Functional Assessment and Change Scale (ADFACS), a functional test assessing the patient s ability to perform instrumental activities of daily living (ADLs) and basic ADLs. Safety results were reported for all patients who received open-label treatment. Statistical analysis Efficacy analyses were performed on observed cases up to week 30 of the open-label treatment (54 weeks since the start of the double-blind studies) and summarised using descriptive statistics. Results of outcome measures were presented as mean change from the baseline score. Statistical analyses were conducted using analysis of covariance for the ADAS-cog. All patients randomised into the open-label extension phase of the study were included in the safety analysis. Results Patient disposition Of the 1219 patients enrolled in the two double-blind studies, 885 (72.6%) continued into the open-label phase. In total, 707 (79.9%) of these 885 patients completed the 30-week open-label extension. A subset of 227 (32.1%) patients continued into the additional extension phase, of whom, 194 (85.5%) completed the additional 36 weeks (Figure 1). A higher proportion of patients randomised to the placebo group during the original double-blind phase discontinued during the 30-week open-label phase (23.6%) compared with the two donepezil groups (19.8 and 16.7% of patients from the original 5 and 10 mg/day donepezil groups, respectively). During the 30-week open-label phase, a total of 108 (12.2%) subjects discontinued prematurely due to AEs: 43 (39.8%) originally randomised to placebo, 36 (33.3%) to 5 mg/day donepezil and 29 (26.9%) to 10 mg/day donepezil. During the additional 36-week extension, 19 (8.4%) of the subset of 227 patients withdrew due to AEs. The most common individual AEs resulting in study withdrawal were cerebrovascular accident (4 [1.3%] placebo and 10 [1.7%] donepezil patients), asthenia (four [1.3%] placebo and six [1.0%] donepezil patients) and nausea (five [1.7%] placebo and four [0.7%] donepezil patients). All other AEs that led to study discontinuation occurred in less than 1% of patients. Patient characteristics No significant differences were found in the baseline characteristics of the patients enrolled in this openlabel study (sex, race, mean age, dementia severity) when compared with those of the initial double-blind studies total cohort. Moreover, demographic characteristics were similar regardless of original treatment group (Table 1). Baseline characteristics of the patients enrolled in the double-blind trials have been described previously (Roman et al., 2005). During the 30-week open-label phase, 111 patients (12.5%) remained on the 5 mg/day dose, 78 patients (8.8%) had their dose increased to 10 mg/day but then returned to 5 mg/day and 696 (78.6%) patients escalated to 10 mg/day donepezil and remained at this dose. Nearly all patients (99.9%) took at least one concomitant medication during the study. These included antithrombotic agents (85.4% of the total population); vitamins (42.8%); agents acting on the renin angiotensin system (36.6%); psychoanaleptics, including hypnotics, antidepressants and tranquillisers (38.2%) and serum lipid-reducing agents (31.4%). Efficacy Cognitive function. Results for the primary outcome measure, the ADAS-cog, showed a mean change from double-blind study baseline score to week 54 (24 weeks double-blind plus 30 weeks open-label) of between 0.6 and 1.15 points for patients who had received donepezil at either dose for the entire 54 weeks (Figure 2A). The mean ADAS-cog score for all the donepezil-treated patients who elected to go into the open-label study improved over baseline during the double-blind trials and remained above baseline for the entire open-label phase of the study. This improvement was observed regardless of the initial randomised dosage (5 or 10 mg of donepezil) during the double-blind phase (Figure 2A). The initiation of donepezil treatment in patients who had been randomised to receive placebo in the
4 308 D. Wilkinson et al. Figure 1 Patient disposition. double-blind trials and who elected to enter the openlabel phase produced no significant improvement in their ADAS-cog scores, but their scores did remain stable, close to their baseline values throughout the additional 30 weeks of treatment (Figure 2A). The MMSE score in both the 5 and 10 mg/day donepezil treatment groups was significantly improved relative to placebo at the end of the double-blind studies and remained improved relative to baseline during the open-label study (Figure 2B). Patients in the delayed start group showed an ameliorated response with a smaller initial improvement, which was maintained above baseline for a shorter time (Figure 2B). Table 1 Patient demographics of the open-label phase Treatment in double-blind phase Placebo n ¼ 301 Donepezil 5 mg/day n ¼ 303 Donepezil 10 mg/day n ¼ 281 Total N ¼ 885 Mean age (SE) 74.6 (0.5) 74.5 (0.5) 74.9 (0.5) 74.7 (0.3) Range Male patients (%) 128 (42.5) 125 (41.3) 112 (39.9) 365 (41.2) Mean ADAS-cog score (SE) 19.0 (0.56) 20.1 (0.57) 20.8 (0.61) 20.0 (0.33) Mean MMSE score (SE) 22.1 (0.23) 22.1 (0.22) 21.7 (0.25) 22.0 (0.14)
5 Long-term use of donepezil for vascular dementia 309 Figure 2 (A) Mean change from baseline ADAS-cog scores during double-blind and open-label treatment. (B) Mean change from baseline MMSE scores during double-blind and open-label treatment. (C) Mean change from baseline CDR-SB scores during double-blind and open-label treatment. (D) Mean change from baseline ADFACS scores during double-blind and open-label treatment. Dosages in figure keys correspond to dosing schedule during double-blind phase only. During the open label extension, all patients received donepezil 5 mg/day for the first 6 weeks and thereafter 10 mg/day, if approved by a clinician (76.6% of patients remained at 10 mg/day through study completion). ol ¼ open label.
6 310 D. Wilkinson et al. Figure 2 (Continued). Global function. Scores on the CDR-SB, which improved from baseline during the double-blind phase for both the 5 and 10 mg/day donepezil groups, remained improved relative to the double-blind study baseline for 42 weeks of treatment (18 weeks openlabel; Figure 2C). As with the ADAS-cog, patients randomised to the delayed start group did not experience an improvement in their CDR-SB scores following the initiation of donepezil treatment in the open-label phase; however, CDR-SB scores were stable
7 Long-term use of donepezil for vascular dementia 311 during the 30 weeks of open-label treatment. At the end of the extension phase, there were no notable differences between the treatment groups. Although there was no significant difference between the groups on the ADFACS scale at endpoint, there was a trend suggesting that patients who had been randomised to 10 mg/day donepezil during the double-blind part of the study declined less during the open-label phase compared with either those receiving donepezil 5 mg/day or the delayed start group (Figure 2D). Tolerability Donepezil was well tolerated. Most AEs were mild to moderate in intensity. No new or unexpected AEs attributable to donepezil emerged during long-term treatment. The AEs that occurred during open-label treatment were the same as those observed during the double-blind studies and they occurred with approximately the same frequency in both phases, with 87.6% of patients in the open-label study and 90.2% of patients in the double-blind studies reporting one or more AE. The only AEs that occurred in more than 10% of patients were diarrhoea (12.8%), accidental injury (12.5%) and infection (11.3%) (Table 2). AEs judged to be related to donepezil treatment resulted from expected cholinergic effects, most commonly nausea (occurring in 5.3% of all patients) and diarrhoea (occurring in 8.8% of all patients). All other drug-related treatment-emergent signs and symptoms occurred in less than 5% of the study population. Treatment-emergent AEs related to the cardiovascular system occurred at a similar rate in treated and placebo patients (28.9% vs. 25.6%, respectively). Of the cardiovascular events recorded during this study, hypertension (6.3% of all patients) and stroke (4.7%) were the most common. There were 29 deaths during the study or within 4 weeks of treatment discontinuation: 7 (2.3%) among patients originally randomised to placebo and 22 (3.8%) among patients originally randomised to donepezil in the double-blind studies. The most common causes of death were cerebrovascular accident, myocardial infarction and malignancy. There were four deaths that investigators attributed possibly to study medication: of these, two patients died of a cardiovascular accident, one from sepsis and one from multisystem failure. Serious AEs were reported for 228 patients. The most common were cerebrovascular accident (4.7%) and accidental injury (2.1%). There were no clinically meaningful changes in clinical laboratory values, vital signs, physical examination findings or electrocardiogram status during the study. Discussion Improvements in cognitive function in patients with VaD gained during the 24-week double-blind treatment with donepezil were maintained above baseline during a further 30 weeks of open-label treatment. Patients receiving donepezil (either dose) for 54 weeks had an improvement in their ADAS-cog score of up to approximately one point from their baseline score, suggesting that continuous treatment with donepezil improves and sustains cognitive benefit for at least a year. Interestingly, although patients receiving 10 mg/ day donepezil initially did better than those patients Table 2 Incidence of most commonly occurring TESS (occurring in 5% of patients) during the open-label phase No. (%) of patients experiencing TESS Treatment in double-blind phase a Placebo n ¼ 301 Donepezil 5 or 10 mg/day n ¼ 584 Total N ¼ 885 Body as a whole 132 (43.9) 270 (46.2) 402 (45.4) Accidental injury 36 (12.0) 75 (12.8) 111 (12.5) Infection 29 (9.6) 71 (12.2) 100 (11.3) Pain 28 (9.3) 36 (6.2) 64 (7.2) Nervous system 136 (45.2) 271 (46.4) 407 (46.0) Cardiovascular system 77 (25.6) 169 (28.9) 246 (27.8) Hypertension 14 (4.7) 42 (7.2) 56 (6.3) Digestive system 119 (39.5) 183 (31.3) 302 (34.1) Diarrhoea 47 (15.6) 66 (11.3) 113 (12.8) Nausea 30 (10.0) 29 (5.0) 59 (6.7) Vomiting 18 (6) 26 (4.5) 44 (5.0) TESS ¼ treatment emergent signs and symptoms. a Dosing during double-blind phase only. During the open label extension, all patients received donepezil 5 mg/day for the first 6 weeks and thereafter 10 mg/day, if approved by a clinician (76.6% of patients remained at 10 mg/day through study completion).
8 312 D. Wilkinson et al. receiving 5 mg/day on this test, after week 34 (i.e. 10 weeks into the open-label phase) patients receiving 5 mg/day donepezil had nonsignificantly better scores on the ADAS-cog that were maintained relative to those of patients receiving 10 mg/day until the end of the study. This pattern has been seen in a previous AD open-label, extension study, where the crossover occurred after about 110 weeks of uninterrupted donepezil therapy (Doody et al., 2001a). The small number of patients in the 5 mg/day group might provide some explanation; however, the reason for this result in the ADAS-cog remains unclear. Both doses of donepezil (5 and 10 mg/day) were beneficial, and in the CDR-SB and the ADFACS tests in this study, the 10 mg/day donepezil dose tended to be the more beneficial dose, suggesting that the discrepant results for the ADAS-cog may be attributable to the variability of the test. By week 42, the mean MMSE score for all patients was one point higher than at baseline. This is in contrast to the decline expected over this period with no treatment. As change in the MMSE score can be directly correlated with clinical measures of function, such as dressing and toileting activities (Galasko et al., 1995), this sustained improvement in the MMSE may represent retention of function, which is important for both patient quality of life (Andersen et al., 2004; Wlodarczyk et al., 2004) and for caregivers. Unlike the ADAS-cog results, MMSE scores attained by patients in the delayed-start group at 42 and 54 weeks were comparable with those of patients who had received donepezil from study start. The ADAS-cog results, however, indicated that there was still a difference in the level of cognitive function between those patients taking donepezil from study start and those with a delay to initiation of active treatment. This may indicate that the ADAS-cog, which was designed specifically to test cognitive deficits associated with AD, is a less sensitive instrument in patients with VaD than the MMSE, which is a general test of cognition. Results with the CDR-SB were similar to those seen with ADAS-cog: that is, improvements gained by the 5 and 10 mg/day donepezil groups during double-blind treatment were mostly maintained above baseline during the open-label phase, but patients who had been delayed in receiving donepezil generally did not improve upon initiation of donepezil treatment. The effects of treatment on function (ADFACS) were mixed. Over the course of the study, the patients ability to carry out ADLs, as measured by this test, generally deteriorated, despite continued donepezil treatment. The evaluation of the ability to perform ADLs in patients with VaD is complicated and can be affected not only by cognition, but also by physical impairments/limitations the patient might have due to stroke, congestive heart failure or to having experienced a heart attack. Nonetheless, once started on therapy, functional ADLs appeared to stabilise in delayed-start patients. The original two double-blind studies only enrolled patients with stable comorbid conditions, often several months (at least 3) after a cardiovascular event. Patients with VaD generally stabilise until the next event, which possibly explains why the original studies showed that efficacy measure scores remained close to baseline among placebo patients (Pratt, 2002), a plateau effect also seen in other VaD clinical trial populations (Kittner et al., 2000). Over time, however, as individual patients experience additional vascular events, accompanied by clinical deterioration either stepwise or, more commonly, gradually this would begin to appear as a progressive group decline. Thus, a positive outcome for this study would include not only a positive result for the treatment group on one or several of the assessment measures, but also stability or less than expected decline. Donepezil was generally well tolerated in this study, in spite of patients having multiple comorbidities and concomitant drug use. Moreover, tolerability data from the 24-week trials were similar to the year-long data, and the extension phase to 90 weeks, albeit with fewer patients. This mirrors what has been observed in clinical studies of AD patients, a population in which safety data are available for up to 4.9 years (Doody et al., 2001b). It is, therefore, not unreasonable to assume that donepezil can be tolerated over the long term in patients with VaD. There are limitations to the present study. The openlabel design of this extension phase does not allow comparison of treated with untreated patients in the longer term. Although not ideal, open-label extension studies do provide important information and are necessary due to the ethical implications of performing long-term, placebo-controlled studies in patients with dementia. Another possible limitation of the study is related to the donepezil dosing schedules. During the double-blind phase, donepezil-treated patients were randomised to receive either the 5 or 10 mg/day dose. On enrolment in the open-label phase, all patients received the 5 mg/day dose for 6 weeks, with some subsequently remaining on this dose, some increasing to the 10 mg/day dose temporarily, and most increasing to the 10 mg/day dose permanently. Although, it is important to consider the possible implications of these different dosage regimens when interpreting the current results, outcomes from the double-blind phase
9 Long-term use of donepezil for vascular dementia 313 Key points Donepezil was well tolerated over 6 months in patients with VaD; 14.4% discontinued due to AEs, with diarrhoea being the most common (incidence of 8.8%). Patients treated with donepezil for 54 continuous weeks (double-blind study plus extension study) had ADAS-cog scores at endpoint that were higher than at baseline, including those who were randomised to donepezil 5 mg/day in the doubleblind trial. Patients who initiated donepezil during the openlabel extension study exhibited no change in ADAS-cog scores. During the extension study no new safety or tolerability issues were observed. do suggest that there is no significant differential effect between the 5 and 10 mg/day doses. An additional weakness is that the study was designed at a time before the value of executive function testing in VaD patients was understood. Therefore, the outcome measures were designed with the cognitive and functional pathology of patients with AD, rather than VaD, in mind. Although there are similarities and overlap in the cognitive dysfunction associated with the two diseases, there are also areas of difference. Patients with VaD, for example, typically demonstrate disproportionate impairment in executive function, particularly visual memory and attention (Cannata et al., 2002). A reasonable set of dysfunctional domains in VaD was properly assessed using a range of tests to measure different aspects of cognition and function given the time when this study and the preceding double-blind studies were initiated. In conclusion, although the lack of a placebo control group prevents absolute statements regarding the longterm efficacy of donepezil in a VaD patient population, the observed trends suggest that it improves cognition and stabilises function in these patients and that improvements are sustained over the long term. Also, patients treated earlier tended to do better in some measures of cognition and global function than those with a delayed start to their treatment. Thus, despite divergent opinions (Kavirajan and Schneider, 2007), donepezil appears to offer a therapeutic alternative for patients with VaD. Acknowledgements This study was sponsored by Eisai Inc. and Pfizer Inc. Study design, data collection and interpretation of the results were conceived by the authors. Editorial assistance was provided by R. Daniel, PhD, at PPSI and was funded by Eisai Inc. and Pfizer Inc. References Andersen CK, Wittrup-Jensen KU, Lolk A, Andersen K, Kragh-Sorensen P Ability to perform activities of daily living is the main factor affecting quality of life in patients with dementia. Health Qual Life Outcomes 2: 52. Black S, Román GC, Geldmacher DS, et al. Donepezil 307 Vascular Dementia Study Group Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke 34: Cannata AP, Alberoni M, Franceschi M, Mariani C Frontal impairment in subcortical ischemic vascular dementia in comparison to Alzheimer s disease. Dement Geriatr Cogn Disord 13: Doody RS, Geldmacher DS, Gordon B, Perdomo CA, Pratt RD. 2001a. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol 58: Doody RS, Stevens JC, Beck C, et al. 2001b. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 56: Dubois MF, Hebert R The incidence of vascular dementia in Canada: a comparison with Europe and East Asia. Neuroepidemiology 20: Galasko D, Edland SD, Morris JC, Clark C, Mohs R, Koss E The consortium to establish a registry for Alzheimer s disease (CERAD). part XI. Clinical milestones in patients with Alzheimer s disease followed over 3 years. Neurology 45: Kavirajan H, Schneider LS Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta analysis of randomised controlled trials. Lancet Neurol 6: Kittner B, De Deyn PP, Erkinjuntti T Investigating the natural course and treatment of vascular dementia and Alzheimer s disease. Parallel study populations in two randomized, placebo-controlled trials. Ann NY Acad Sci 903: Pratt RD Patient populations in clinical trials of the efficacy and tolerability of donepezil in patients with vascular dementia. J Neurol Sci : Roman GC, Wilkinson DG, Doody RS, Black SE, Salloway SP, Schindler RJ Donepezil in vascular dementia: combined analysis of two largescale clinical trials. Dement Geriatr Cogn Disord 20: Roman G, Black S, Royall DR, et al Efficacy and safety of donepezil in vascular dementia: results from the largest double-blind trial in vascular dementia patients. Eur Neuropsychopharm 16 (Suppl 4): S481 S482. Tohgi H, Abe T, Kimura M, Saheki M, Takahashi S Cerebrospinal fluid acetylcholine and choline in vascular dementia of Binswanger and multiple small infarct types as compared with Alzheimer-type dementia. J Neural Transm 103: Wilkinson D, Doody R, Helme R, et al. Donepezil 308 Study Group Donepezil in vascular dementia: a randomized, placebo-controlled study. Neurology 61: Wlodarczyk JH, Brodaty H, Hawthorne G The relationship between quality of life, mini-mental state examination, and the instrumental activities of daily living in patients with Alzheimer s disease. Arch Gerontol Geriatr 39:
Efficacy of Donepezil Treatment in Alzheimer Patients with and without Subcortical Vascular Lesions
Short Communication Pharmacology 2004;72:1 5 DOI: 10.1159/000078625 Received: January 27, 2004 Accepted after revision: February 23, 2004 Efficacy of Donepezil Treatment in Alzheimer Patients with and
More informationKnown as both a thief and murderer,
&A Dementia Drugs: When Should They Be Stopped? Ron Keren, MD, FRCPC As presented at the University of Toronto s Primary Care Conference, Toronto, Ontario (May 25) Known as both a thief and murderer, Alzheimer
More informationDonepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer s disease (amended)
Issue date: November 2006 (amended September 2007) Review date: September 2009 Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer s disease (amended) Includes a
More informationDonepezil, (R,S)-1-benzyl-4[(5,6 dimethoxy-1-indanon)- Update on Alzheimer Drugs (Donepezil) ORIGINAL ARTICLE. Rachelle Smith Doody, MD, PhD
ORIGINAL ARTICLE Update on Alzheimer Drugs (Donepezil) Rachelle Smith Doody, MD, PhD Background: Several clinical trials have been conducted over a period of many years reporting the benefits of donepezil
More informationDementia of the Alzheimer Type: the Drug Treatment Debate
Dementia of the Alzheimer Type: the Drug Treatment Debate I have no financial conflict of interest. Many years ago I was given a trip to San Fran and taught to use a slide set from the drug company. I
More informationManagement of cognition and function: new results from the clinical trials programme of Aricept (donepezil HCl)
International Journal of Neuropsychopharmacology (2000), 3 (Supplement 2), S13 S20. Copyright 2000 CINP Management of cognition and function: new results from the clinical trials programme of Aricept (donepezil
More informationAppendix 5. Characteristics of included studies. Study title: NCT
Appendix 5 Characteristics of included studies Study title: NCT00818662 Study design: 'A Randomized, Double-Blind, Placebo-led, Two Dose Arm, Parallel Study of the Safety and Effectiveness of Immune Globulin
More informationTitle of Study: Evaluation of Efficacy and Safety of Galantamine in Patients With Dementia of Alzheimer's Type Who Failed to Benefit From Donepezil
SYNOPSIS Name of Sponsor/Company Name of Finished Product REMINYL Name of Active Ingredient(s) Galantamine hydrobromide Issue Date: 18 October 2013 Protocol No.: Title of Study: Evaluation of Efficacy
More informationSYNOPSIS. Trial No.: RIS-USA-70 Clinical phase: III. JRF, Clinical Research Report RIS-USA-70, 16 October, 1998 N Trial period: Start: 20 Nov 95
SYNOPSIS Trial identification and protocol summary Company: Janssen Research Foundation Finished product: RISPERDAL Active ingredient: Risperidone (R064,766) Title: An open-label, long-term study of risperidone
More informationVascular Dementia. Laura Pedelty, PhD MD The University of Illinois at Chicago and Jesse Brown VA Medical Center
Vascular Dementia Laura Pedelty, PhD MD The University of Illinois at Chicago and Jesse Brown VA Medical Center none Disclosures Objectives To review the definition of Vascular Cognitive Impairment (VCI);
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationAssessment report. for
Assessment report for FABRAZYME agalsidase beta Assessment report on the shortage of Fabrazyme Overview of Shortage Period: Spontaneous Reports from June 2009 through 15 September and Registry Data from
More informationPrimary Endpoint The primary endpoint is overall survival, measured as the time in weeks from randomization to date of death due to any cause.
CASE STUDY Randomized, Double-Blind, Phase III Trial of NES-822 plus AMO-1002 vs. AMO-1002 alone as first-line therapy in patients with advanced pancreatic cancer This is a multicenter, randomized Phase
More informationExecutive Summary. The Royal Australasian College of Physicians July 2012 Page 1 of 5
PBAC Review of Pharmaceutical Benefits Scheme anti-dementia drugs to treat Alzheimer s disease Submission by The Royal Australasian College of Physicians July 2012 The Royal Australasian College of Physicians
More informationSYNOPSIS. Risperidone-R064766: Clinical Study Report RIS-USA-232 (FOR NATIONAL AUTHORITY USE ONLY)
SYNOPSIS Protocol No.: RIS-USA-232 Title of Study: Efficacy and Safety of a Flexible Dose of Risperidone Versus Placebo in the Treatment of Psychosis of Alzheimer's Disease Principal Investigator: M.D.
More informationEfficacy of Levetiracetam: A Review of Three Pivotal Clinical Trials
Epilepsia, 42(Suppl. 4):31 35, 2001 Blackwell Science, Inc. International League Against Epilepsy Efficacy of : A Review of Three Pivotal Clinical Trials Michael Privitera University of Cincinnati Medical
More informationPFIZER INC. Study Initiation Date and Completion Dates: 09 March 2000 to 09 August 2001.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationBioArctic announces detailed results of the BAN2401 Phase 2b study in early Alzheimer s disease presented at AAIC 2018
Press release BioArctic announces detailed results of the BAN2401 Phase 2b study in early Alzheimer s disease presented at AAIC 2018 Stockholm, Sweden, July 25, 2018 BioArctic AB (publ) (Nasdaq Stockholm:
More informationEXPEDITION3: A Phase 3 Trial of Solanezumab in Mild Dementia due to Alzheimer s Disease
EXPEDITION3: A Phase 3 Trial of in Mild Dementia due to Alzheimer s Disease Lawrence S. Honig, MD, PhD On behalf of the EXPEDITION3 Study Team Disclosure Statement I will discuss investigational use only.
More informationPFIZER INC. Study Initiation Date and Primary Completion or Completion Dates: 11 November 1998 to 17 September 1999
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationSeptember 26 28, 2013 Westin Tampa Harbour Island. Co-sponsored by
September 26 28, 2013 Westin Tampa Harbour Island Co-sponsored by From Brains at Risk to Cognitive Dysfunction: The Role of Vascular Pathology Ralph Sacco, MD, MS, FAHA, FAAN Miller School of Medicine
More informationBiogen, Cambridge, MA, USA; 2 Cytel, Cambridge, MA, USA; 3 Neurimmune, Schlieren-Zurich, and University of Zurich, Switzerland
Aducanumab 36-Month Data From PRIME: A Randomized, Double-Blind, Placebo-Controlled Phase 1b Study in Patients With Prodromal or Mild Alzheimer s Disease Samantha Budd Haeberlein, PhD 1, Sarah Gheuens,
More informationCholinesterase inhibitors for Alzheimer s disease (Review)
Birks J This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2008, Issue 3 http://www.thecochranelibrary.com 1 T A B L E O
More informationMeasure #282: Dementia: Functional Status Assessment National Quality Strategy Domain: Effective Clinical Care
Measure #282: Dementia: Functional Status Assessment National Quality Strategy Domain: Effective Clinical Care 2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Process DESCRIPTION: Percentage
More informationDrugs for dementia: the first year
The Ulster Medical Journal, Volume 69, No. 2, pp. 123-127, November 2000. Drugs for dementia: the first year An audit of prescribing practice G McGirr, S A Compton Accepted 12 September 2000 SUMMARY In
More informationCLINICAL TRIALS SECTION EDITOR: IRA SHOULSON, MD. Efficacy of Donepezil in Early-Stage Alzheimer Disease
CLINICAL TRIALS SECTION EDITOR: IRA SHOULSON, MD Efficacy of Donepezil in Early-Stage Alzheimer Disease A Randomized Placebo-Controlled Trial Ben Seltzer, MD; Parvaneh Zolnouni, MD; Margarita Nunez, MD;
More informationRecommendations For the Use of Donepezil
Recommendations For the Use of Donepezil The trial of donepezil in patients with mild to moderate dementia due to probable AD was one recommendation made by the Canadian Consensus Conference on Dementia.
More informationORIGINAL CONTRIBUTION. Response of Patients With Alzheimer Disease to Rivastigmine Treatment Is Predicted by the Rate of Disease Progression
ORIGINAL CONTRIBUTION Response of Patients With Alzheimer Disease to Rivastigmine Treatment Is Predicted by the Rate of Disease Progression Martin R. Farlow, MD; Ann Hake, MD; John Messina, PharmD; Richard
More information42-Lowering Agent, in Alzheimer s s Disease: A Phase 2 Trial of up to 24 Months of Treatment. Gordon K. Wilcock*, University of Oxford, UK
Efficacy and Safety of Tarenflurbil (Flurizan ), a Selective Aβ42A 42-Lowering Agent, in Alzheimer s s Disease: A Phase 2 Trial of up to 24 Months of Treatment Gordon K. Wilcock*, University of Oxford,
More informationPFIZER INC. Study Initiation Date and Completion Dates: Information not available (Date of Statistical Report: 16 May 2004)
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (Review of TA 111) Appraisal
More informationSupplementary Online Content
Supplementary Online Content Atri A, Frölich L, Ballard C, et al. Effect of idalopirdine as adjunct to cholinesterase inhibitors on in cognition in patients with Alzheimer disease: three randomized clinical
More informationSponsor. Generic drug name. Trial indication(s) Protocol number. Protocol title. Phase of Drug Development. Study Start/End Dates
Sponsor Novartis Generic drug name SAB378 [Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone] Trial indication(s) Postherpetic neuralgia (PHN) Protocol number CSAB378A2201 Protocol title A multicenter,
More information2. SYNOPSIS Name of Sponsor/Company:
in patients with refractory partial seizures 14 Jun 2007 2. SYNOPSIS TITLE OF STUDY: Efficacy and safety of BIA 2-093 as adjunctive therapy for refractory partial seizures in a double-blind, randomized,
More informationMonth/Year of Review: September 2013 Date of Last Review: February 2012
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119 Copyright 2012 Oregon State University. All Rights
More informationQuality ID #282: Dementia: Functional Status Assessment National Quality Strategy Domain: Effective Clinical Care
Quality ID #282: Dementia: Functional Status Assessment National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Process DESCRIPTION:
More informationRESEARCH AND PRACTICE IN ALZHEIMER S DISEASE VOL 10 EADC OVERVIEW B. VELLAS & E. REYNISH
EADC BRUNO VELLAS 14/01/05 10:14 Page 1 EADC OVERVIEW B. VELLAS & E. REYNISH (Toulouse, France, EU) Bruno Vellas: The European Alzheimer's Disease Consortium is a European funded network of centres of
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationDronedarone for the treatment of non-permanent atrial fibrillation
Dronedarone for the treatment of non-permanent atrial Issued: August 2010 last modified: December 2012 guidance.nice.org.uk/ta197 NICE has accredited the process used by the Centre for Health Technology
More informationClinical Trial Results Summary Study EN3409-BUP-305
Title of Study: A 52-Week, Open-Label, Long-Term Treatment Evaluation of the Safety and Efficacy of BEMA Buprenorphine in Subjects with Moderate to Severe Chronic Pain Coordinating Investigator: Martin
More informationC holinomimetic drugs constitute the first line of treatment
310 PAPER Cholinesterase inhibitor treatment alters the natural history of Alzheimer s disease O L Lopez, J T Becker, S Wisniewski, J Saxton, D I Kaufer, S T DeKosky... See end of article for authors affiliations...
More informationTRANSPARENCY COMMITTEE
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 18 December 2013 EXELON 13.3 mg/24 hours, transdermal patch B/30 sachets (CIP: 34009 268 908 1 0) Applicant: NOVARTIS
More informationLiterature Scan: Alzheimer s Drugs
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objective:
GSK Medicine: abacavir (ABC)/dolutegravir (DTG)/lamivudine (3TC) Study Number: 201147 Title: A IIIb, randomized, open-label study of the safety, efficacy, and tolerability of switching to a fixed-dose
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationClinical Trial Study Synopsis
Clinical Trial Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website and is provided for patients and healthcare professionals to increase the transparency
More informationAcetylcholinesterase inhibitors: donepezil, rivastigmine, tacrine or galantamine for non-alzheimer s dementia
STEER 2002; Vol 2: No.2 Acetylcholinesterase inhibitors: donepezil, rivastigmine, tacrine or galantamine for non-alzheimer s dementia Bunmi Fajemisin Evidence search date: November 2001 www.signpoststeer.org
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationSCIENTIFIC DISCUSSION
London, 2 March 2006 Product name: Prometax Procedure number: EMEA/H/C/255/II/33 SCIENTIFIC DISCUSSION 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 86
More informationRegulatory Challenges across Dementia Subtypes European View
Regulatory Challenges across Dementia Subtypes European View Population definition including Early disease at risk Endpoints in POC studies Endpoints in pivotal trials 1 Disclaimer No CoI The opinions
More informationReview Article Broader Considerations of Higher Doses of Donepezil in the Treatment of Mild, Moderate, and Severe Alzheimer s Disease
International Alzheimer s Disease Volume 2012, Article ID 707468, 4 pages doi:10.1155/2012/707468 Review Article Broader Considerations of Higher Doses of Donepezil in the Treatment of Mild, Moderate,
More informationDEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017.
DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017. Introduction. Parkinson's disease (PD) has been considered largely as a motor disorder. It has been increasingly recognized that
More informationDEMENTIA NEWSLETTER for PHYSICIANS
DEMENTIA NEWSLETTER for PHYSICIANS Vol. 6, No. 4 OTTAWA AND RENFREW COUNTY Winter 2008 In This Issue... Mild Cognitive Impairment Monitoring Patient Response to Cognitive Enhancers CDN Diagnostic Assessment
More informationSponsor Novartis. Generic Drug Name. NA (not existing yet) Therapeutic Area of Trial Parkinson s Disease L-dopa induced dyskinesia
Page 1 Sponsor Novartis Generic Drug Name NA (not existing yet) Therapeutic Area of Trial Parkinson s Disease L-dopa induced dyskinesia Approved Indication Investigational. Study Number CA2206 Title A
More informationResults from RE-LY and RELY-ABLE
Results from RE-LY and RELY-ABLE Assessment of the safety and efficacy of dabigatran etexilate (Pradaxa ) in longterm stroke prevention EXECUTIVE SUMMARY Dabigatran etexilate (Pradaxa ) has shown a consistent
More informationDESCRIPTION: Percentage of patients with dementia for whom an assessment of functional status was performed at least once in the last 12 months
Quality ID #282: Dementia: Functional Status Assessment National Quality Strategy Domain: Effective Clinical Care Meaningful Measure Area: Prevention, Treatment, and Management of Mental Health 2019 COLLECTION
More informationSynopsis Style Clinical Study Report SR EFC10139 Version number: 1 (electronic 2.0)
SYNOPSIS Title of the study: A randomized, double-blind, parallel-group, multicenter, multinational study to assess the long-term effect, over 1 year, of rimonabant 10 mg in comparison with rimonabant
More informationCombination therapy compared to monotherapy for moderate to severe Alzheimer's Disease. Summary
Combination therapy compared to monotherapy for moderate to severe Alzheimer's Disease Summary Mai 17 th 2017 Background Alzheimer s disease is a serious neurocognitive disorder which is characterized
More informationSYNOPSIS (PROTOCOL WX17796)
TITLE OF THE STUDY A prospective, randomized, double-blind, placebo-controlled, parallel group, multicenter, 52-week trial to assess the efficacy and safety of adjunct MMF to achieve remission with reduced
More information2.0 Synopsis. Choline fenofibrate capsules (ABT-335) M Clinical Study Report R&D/06/772. (For National Authority Use Only) Name of Study Drug:
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: Volume: Choline Fenofibrate (335) Name of Active Ingredient:
More informationSponsor. Novartis Pharmaceuticals Corporation Generic Drug Name. Agomelatine Therapeutic Area of Trial. Major depressive disorder Approved Indication
Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Corporation Generic Drug Name Therapeutic Area of Trial Major depressive disorder Approved Indication Investigational drug Study
More informationIan McKeith MD, F Med Sci, Professor of Old Age Psychiatry, Newcastle University
Ian McKeith MD, F Med Sci, Professor of Old Age Psychiatry, Newcastle University Design of trials in DLB and PDD What has been learnt from previous trials in these indications and other dementias? Overview
More information8/14/2018. The Evolving Concept of Alzheimer s Disease. Epochs of AD Research. Diagnostic schemes have evolved with the research
The Evolving Concept of Alzheimer s Disease David S. Geldmacher, MD, FACP Warren Family Endowed Chair in Neurology Department of Neurology UAB School of Medicine Epochs of AD Research Epoch Years Key Event
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationWHAT IS DEMENTIA? An acquired syndrome of decline in memory and other cognitive functions sufficient to affect daily life in an alert patient
DEMENTIA WHAT IS DEMENTIA? An acquired syndrome of decline in memory and other cognitive functions sufficient to affect daily life in an alert patient Progressive and disabling Not an inherent aspect of
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See United States Package Insert (USPI)
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationJanssen-Cilag EMEA Medical Affairs a division of Janssen Pharmaceuticals N.V.
SYNOPSIS Issue Date: Final 22 July 2009 [Document No.: EDMS-PSDB-9245102] Name of Sponsor/Company Name of Finished Product Risperdal Consta Name of Active Ingredient(s) Protocol No.: RIS-BMN-3001 Janssen-Cilag
More informationBRL /RSD-101RLL/1/CPMS-716. Report Synopsis
Report Synopsis Study Title: A Multicenter, Open-label, Six-Month Extension Study to Assess the Long-term Safety of Paroxetine in Children and Adolescents with Major Depressive Disorder (MDD) or Obsessive-Compulsive
More informationIt is only in the past decade that pharmacologic
IS THERE TREATMENT FOR ALZHEIMER S DISEASE? Gary M. Levin, PharmD, BCPP, FCCP * ABSTRACT There are now 5 approved drugs for the primary symptoms of Alzheimer s disease (AD), 4 of which inhibit acetylcholinesterase
More informationDRUG THERAPY CHOICES FOR THE DEMENTED PATIENT Past, Present and Future
DRUG THERAPY CHOICES FOR THE DEMENTED PATIENT Past, Present and Future Daniel S. Sitar Professor Emeritus University of Manitoba Email: Daniel.Sitar@umanitoba.ca March 6, 2018 INTRODUCTION EPIDEMIOLOGY
More informationBioArctic announces positive topline results of BAN2401 Phase 2b at 18 months in early Alzheimer s Disease
Press release BioArctic announces positive topline results of BAN2401 Phase 2b at 18 months in early Alzheimer s Disease The full 18 month analysis of the 856 patient BAN2401 Phase 2b clinical study in
More informationFull Novartis CTRD Results Template
Full Novartis CTRD Results Template Sponsor Novartis Generic Drug Name vildagliptin Therapeutic Area of Trial Type 2 diabetes Approved Indication Type 2 diabetes Protocol Number CLAF237A23137E1 Title A
More informationClinical Trial Synopsis TL-OPI-518, NCT#
Clinical Trial Synopsis, NCT# 00225264 Title of Study: A Double-Blind, Randomized, Comparator-Controlled Study in Subjects With Type 2 Diabetes Mellitus Comparing the Effects of Pioglitazone HCl vs Glimepiride
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationTrial Designs and Outcomes to Monitor Novel Therapeutics in Alzheimer s Disease
2 Trial Designs and Outcomes to Monitor Novel Therapeutics in Alzheimer s Disease Serge Gauthier Introduction The various etiological hypotheses for Alzheimer s disease (AD) need to be tested in patients
More informationSYNOPSIS. Risperidone-R064766: Clinical Study Report RIS-AUS-5 (FOR NATIONAL AUTHORITY USE ONLY)
SYNOPSIS Protocol No.: RIS-AUS-5 Psychosis in Alzheimer s disease (PAD) analysis Title of Study: Risperidone in the treatment of behavioral and psychological symptoms in dementia: a multicenter, double-blind,
More information2.0 Synopsis. Adalimumab M Clinical Study Report R&D/04/900. (For National Authority Use Only) Referring to Part of Dossier: Volume:
2. Synopsis Abbott Laboratories Name of Study Drug: Name of Active Ingredient: Title of Study: Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority Use Only) Phase
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationNeuropsychiatric Manifestations in Vascular Cognitive Impairment Patients with and without Dementia
86 Neuropsychiatric Manifestations in Vascular Cognitive Impairment Patients with and without Dementia Pai-Yi Chiu 1,3, Chung-Hsiang Liu 2, and Chon-Haw Tsai 2 Abstract- Background: Neuropsychiatric profile
More informationAAIC 2018, Chicago, Illinois, US. July 22, 2018
24-Month Analysis of Change From Baseline In Clinical Dementia Rating Scale Cognitive and Functional Domains in PRIME, A Randomized Phase b Study of the Anti-Amyloid Beta Monoclonal Antibody Aducanumab
More informationBRL /RSD-101C0F/1/CPMS-716. Report Synopsis
Report Synopsis Study Title: A Multicenter, Open-label, Six-Month Extension Study to Assess the Long-Term Safety of Paroxetine in Children and Adolescents with Major Depressive Disorder (MDD) or Obsessive-Compulsive
More informationEstimating the Validity of the Korean Version of Expanded Clinical Dementia Rating (CDR) Scale
Estimating the Validity of the Korean Version of Expanded Clinical Dementia Rating (CDR) Scale Seong Hye Choi, M.D.*, Duk L. Na, M.D., Byung Hwa Lee, M.A., Dong-Seog Hahm, M.D., Jee Hyang Jeong, M.D.,
More informationSponsor Novartis. Generic Drug Name. Valsartan and amlodipine Trial Indication(s) Hypertension Protocol Number CVAA489A2306 Protocol Title
Sponsor Novartis Generic Drug Name Valsartan and amlodipine Trial Indication(s) Hypertension Protocol Number CVAA489A2306 Protocol Title A randomized, double-blind, multi-center, active-controlled, parallel
More informationClinical Policy: Rivastigmine (Exelon) Reference Number: CP.PMN.101 Effective Date: Last Review Date: 02.18
Clinical Policy: (Exelon) Reference Number: CP.PMN.101 Effective Date: 03.01.17 Last Review Date: 02.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE. Opinion. 1 October 2008
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 1 October 2008 EFFEXOR SR 37.5 mg prolonged-release capsule B/30 (CIP: 346 563-3) EFFEXOR SR 75 mg prolonged-release
More informationSYNOPSIS. Administration: subcutaneous injection Batch number(s):
SYNOPSIS Title of the study: A randomized, double-blind, placebo-controlled, 2-arm parallel-group, multicenter 24-week study followed by an extension assessing the efficacy and safety of AVE0010 on top
More informationMild Cognitive Impairment Symposium January 19 and 20, 2013
Highlights of Biomarker and Clinical Outcomes in Recent AD Treatment Trials Stephen Salloway, MD, MS Professor of Neurology and Psychiatry Alpert Medical School, Brown University Mild Cognitive Impairment
More informationSYNOPSIS. Study Coordinator. Study centre(s)
Drug product: Seroquel Drug substance(s): Quetiapine Document No.: 1 Edition No.: 1 Study code: D1449C00005 Date: 02 January 2007 SYNOPSIS A Randomized, Parallel Group, Open Trial Examining the Safety,
More informationTechnology appraisal guidance Published: 23 March 2011 nice.org.uk/guidance/ta217
Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease Technology appraisal guidance Published: 23 March 2011 nice.org.uk/guidance/ta217 NICE 2017. All rights reserved.
More informationBritish Geriatrics Society
Healthcare professional group/clinical specialist statement Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Healthcare
More informationSYNOPSIS. Clinical Study Report CN138002: Addendum 1. Individual Study Table Referring to the Dossier
Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Abilify Name of Active Ingredient: aripiprazole Individual Study Table Referring to the Dossier (For National Authority Use Only)
More informationThe prevalence of Alzheimer s disease
GERIATRIC MEDICINE Maintaining Patients With Alzheimer s Disease in the Home Environment David S. Geldmacher, MD ABSTRACT The prevalence of the most common form of dementia, Alzheimer s disease (AD), is
More informationSYNOPSIS. ER OROS Paliperidone: Clinical Study Report R SCH-301
SYNOPSIS Protocol No.: R076477-SCH-301 Title of Study: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With an Open-Label Extension Evaluating Extended Release OROS Paliperidone in
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationClinical Trial Synopsis TL-OPI-516, NCT#
Clinical Trial Synopsis, NCT#00225277 Title of Study: A Double-Blind, Randomized, Comparator-Controlled Study in Subjects With Type 2 Diabetes Mellitus Comparing the Effects of Pioglitazone HCl Versus
More informationClinical Trial Results Database Page 1
Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name Therapeutic Area of Trial L-dopa induced dyskinesias in Parkinson s disease (PD-LID) Approved Indication Not approved yet for any
More informationStudy Center(s): The study was conducted at 39 study sites in Japan.
SYNOPSIS Issue Date: 20 NOVEMBER 2012 Name of Sponsor/Company Janssen Pharmaceutical K. K. Name of Finished Product CONCERTA Name of Active Ingredient(s) Methylphenidate HCl Protocol No.: JNS001-JPN-A01
More informationA 24-Week, Open-Label Extension Study to Investigate the Long-Term Safety,
1 A 24-Week, Open-Label Extension Study to Investigate the Long-Term Safety, Tolerability, and Efficacy of 13.3 mg/24 h Rivastigmine Patch in Patients with Severe Alzheimer s Disease Martin R. Farlow,
More informationMild versus moderate stages of Alzheimer's disease: three-year outcomes in a routine clinical setting of cholinesterase inhibitor therapy
Wattmo et al. Alzheimer's Research & Therapy (2016) 8:7 DOI 10.1186/s13195-016-0174-1 RESEARCH Open Access Mild versus moderate stages of Alzheimer's disease: three-year outcomes in a routine clinical
More information